文献速递妇科生殖医学

褪黑素活性与受体在人子宫内膜及子宫内膜异位症组织中的表达

Melatonin activity and receptor expression in endometrial tissue and endometriosis.
PubMed 文献 · Hum Reprod · 2019-01-01

基础研究检测人子宫内膜与子宫内膜异位症组织中褪黑素受体MR1A和MR1B的表达,并观察褪黑素对子宫内膜上皮细胞增殖的影响。腹膜病灶中两种受体mRNA表达显著高于子宫内膜瘤和在位内膜,但MR1A蛋白表达低于对照组在位内膜。褪黑素(0.1 nM-1.0 μM)在培养48小时抑制雌二醇(1.0 nM)诱导的子宫内膜上皮细胞增殖,24小时无此作用。

要点

  • MR1A和MR1B在在位子宫内膜、子宫内膜瘤和腹膜病灶中均有表达,但程度不同。
  • 腹膜病灶MR1A和MR1B mRNA表达显著高于子宫内膜瘤和在位内膜。
  • 褪黑素在48小时抑制雌二醇诱导的子宫内膜上皮细胞增殖,24小时无抑制作用。

核心结论

  • 褪黑素受体在人在位子宫内膜、子宫内膜瘤和腹膜病灶中表达,程度不同;褪黑素在培养中减弱雌二醇诱导的子宫内膜上皮细胞增殖。

研究设计与样本

  • 基础科学研究,使用人子宫内膜组织和子宫内膜上皮细胞系(CRL-1671)。
  • 手术确诊子宫内膜异位症女性(子宫内膜瘤n=20或仅腹膜病灶n=11)及无子宫内膜异位症手术证据的对照女性(n=15)。
  • 检测褪黑素受体mRNA和蛋白表达,收集妇科病史和人口学信息;在培养24和48小时后量化雌二醇(1.0 nM)和褪黑素(0.1 nM-1.0 μM)±雌二醇诱导的子宫内膜上皮细胞增殖。

主要发现

  • MR1A和MR1B通过免疫组化定位于有和无子宫内膜异位症女性子宫内膜活检的腺上皮细胞。
  • 两种受体在在位和异位子宫内膜组织中均有表达。
  • 腹膜病灶中MR1A和MR1B mRNA表达显著高于子宫内膜瘤或在位子宫内膜。
  • 腹膜病灶中MR1A蛋白表达低于对照在位子宫内膜,而MR1B表达在组间无差异。
  • 褪黑素(0.1 nM-1.0 μM)在培养48小时抑制雌二醇(1.0 nM)诱导的子宫内膜上皮细胞增殖,24小时无抑制作用。

关键数值与推荐

  • 雌二醇浓度1.0 nM;褪黑素浓度范围0.1 nM-1.0 μM;培养时间24和48小时。

临床怎么用

  • 作者认为褪黑素可能作为当前子宫内膜异位症治疗的辅助手段。

局限性

  • 在培养中观察到的褪黑素有益效应尚未在子宫内膜异位症女性中全面评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are melatonin receptors (melatonin receptor 1A (MR1A) and melatonin receptor 1B (MR1B)) expressed in human endometrium and endometriotic tissue, and does melatonin affect endometrial cell proliferation? SUMMARY ANSWER: Melatonin receptors are expressed in human eutopic endometrium, endometriomas and peritoneal lesions, although to different extents, and melatonin treatment attenuated estradiol-induced endometrial epithelial cell proliferation in culture. WHAT IS KNOWN ALREADY: Melatonin decreased endometriotic lesion volume in a rat model of endometriosis. Melatonin treatment reduced pain scores in and analgesic use by women with endometriosis. STUDY DESIGN, SIZE, DURATION: Basic science study using human endometrial tissue and an endometrial epithelial cell line. PARTICIPANTS/MATERIALS, SETTING, METHODS: Measurement of melatonin receptor expression (mRNA and protein) in women with surgically confirmed endometriosis (endometrioma (n = 20) or peritoneal lesion (n = 11) alone) and women without surgical evidence of endometriosis (control, n = 15). Collection of endometrial and endometriotic tissue samples, gynecologic history and demographic information. Quantification of estradiol (1.0 nM) and melatonin (0.1 nM-1.0 μM) ± estradiol-induced endometrial epithelial cell proliferation in cultures of endometrial epithelial cells (CRL-1671) following 24 and 48 hours of culture. MAIN RESULTS AND THE ROLE OF CHANCE: MR1A and MR1B were localized by immunohistochemistry in glandular epithelial cells of endometrial biopsies from women with and without endometriosis. Both receptors were expressed in eutopic and ectopic endometrial tissue. mRNA expression of MR1A and MR1B was significantly greater in peritoneal lesions than in either endometriomas or eutopic endometrium. However, protein expression of MR1A was decreased in peritoneal lesions compared to control eutopic endometrium, whereas MR1B expression did not differ between the groups. Melatonin (0.1 nM-1.0 μM) treatment inhibited estradiol (1.0 nM)-induced endometrial epithelial cell proliferation at 48 hours but not 24 hours of culture. LIMITATIONS, REASONS FOR CAUTION: Beneficial effects of melatonin seen in culture have yet to be comprehensively evaluated in women with endometriosis. WIDER IMPLICATIONS OF THE FINDINGS: Our data suggest that melatonin may be useful as an adjunct to current endometriosis treatments. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the Canadian Institutes of Health Research (grant MOP142230 to W.G.F.). A.A.M. is supported by a resident research grant through the Physicians Services Incorporated Foundation. The authors have no conflicts of interest.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Mosher AA, Tsoulis MW, Lim J, et al. Melatonin activity and receptor expression in endometrial tissue and endometriosis. Hum Reprod. 2019. PMID: 31211323. doi:10.1093/humrep/dez082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。